Sign inJoin waitlistJoin the waitlist

Robin Hanson

Physician · Mercy Children's Hospital St. Louis

Credentials: · · · ·

History

Mercy Children's Hospital St. Louis
2021–Present

Howard Hughes Medical Institute
1996–1999
St. Louis Children's Hospital-Pediatric Residency-Pediatric Hematology-Oncology
1993–1996
Washington University School of Medicine
1989–1993

Research

MLL, a mammalian trithorax-group gene, functions as a transcriptional maintenance factor in morphogenesis
Proceedings of the National Academy of Sciences of the United States of America · 1998 · 261 citations
Defects in yolk sac hematopoiesis in Mll-null embryos
Blood · 1997 · 215 citations
Mammalian Trithorax and polycomb-group homologues are antagonistic regulators of homeotic development
Proceedings of the National Academy of Sciences of the United States of America · 1999 · First of 11 authors · 197 citations

TL
Timothy Ley
9 papers
Jay Hess
3 papers
AB
Adam Buchanan
1 paper
BY
Benjamin Yu
1 paper
Brian Greffe
1 paper
CS
Colin Sieff
1 paper
CH
Craig Hurwitz
1 paper
David Franz
1 paper
DM
Desiree Medeiros
1 paper
George Caughey
1 paper
HK
Howard Kelfer
1 paper
Jennifer Rothman
1 paper

Clinical trials

A Study Comparing Higher Dose Chemotherapy Over a Shorter Amount of Time to Lower Dose Chemotherapy Plus Maintenance Over a Longer Amount of Time in Patients With Newly Diagnosed Intermediate-Risk Rhabdomyosarcoma (IR RMS)
Site PI · Recruiting · Phase 3
Children's Oncology Group
2026–2031
Testing the Addition of the Anti-cancer Drug Venetoclax and/or the Anti-cancer Immunotherapy Blinatumomab to the Usual Chemotherapy Treatment for Infants With Newly Diagnosed KMT2A-rearranged or KMT2A-non-rearranged Leukemia
Site PI · Recruiting · Phase 2
National Cancer Institute (NCI)
2025–2028
Dinutuximab With Chemotherapy, Surgery and Stem Cell Transplantation for the Treatment of Children With Newly Diagnosed High Risk Neuroblastoma
Site PI · Recruiting · Phase 3
National Cancer Institute (NCI)
2024–2029
A Study With Tovorafenib (DAY101) as a Treatment Option for Progressive, Relapsed, or Refractory Langerhans Cell Histiocytosis
Site PI · Recruiting · Phase 2
National Cancer Institute (NCI)
2024–2028